These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199 [TBL] [Abstract][Full Text] [Related]
8. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis. Kho S; Seung KJ; Huerga H; Bastard M; Khan PY; Mitnick CD; Rich ML; Islam S; Zhizhilashvili D; Yeghiazaryan L; Nikolenko EN; Zarli K; Adnan S; Salahuddin N; Ahmed S; Vargas ZHR; Bekele A; Shaimerdenova A; Tamirat M; Gelin A; Vilbrun SC; Hewison C; Khan U; Franke M Nat Commun; 2024 May; 15(1):3927. PubMed ID: 38724531 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia. Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383 [TBL] [Abstract][Full Text] [Related]
10. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
12. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis. Bhatnagar AK; Hemanthkumar AK; Muthu Vijayalakshmi M; Vohra V; Padmapriyadarsini C; Ramesh PM; Taneja G; Chavan VN; Jeyadeepa B; Bhui NK; Solanki R Ther Drug Monit; 2024 Jun; 46(3):363-369. PubMed ID: 38161267 [TBL] [Abstract][Full Text] [Related]
13. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis. Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid. Chen Q; Huang T; Zou L; Tang X; Shi Z; Wang X; Wu H; Sun J; Lu X; Liang L; Jiang L; Liu D; Tang S; Wu G; He W Sci Rep; 2024 Jul; 14(1):17347. PubMed ID: 39069547 [TBL] [Abstract][Full Text] [Related]
15. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469 [TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review. Putra ON; Yulistiani Y; Soedarsono S; Subay S Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755 [TBL] [Abstract][Full Text] [Related]
17. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis. Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392 [No Abstract] [Full Text] [Related]
18. Delamanid for multidrug-resistant pulmonary tuberculosis. Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901 [TBL] [Abstract][Full Text] [Related]
19. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276 [TBL] [Abstract][Full Text] [Related]
20. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]